This is a randomised, double-blind, placebo-controlled clinical trial intended to evaluate the safety, tolerability and pharmacokinetic profiles of HW243040 following single and multiple administrations in healthy study participants.
Inclusion Criteria:
Exclusion Criteria:
liulifei@renfu.com.cn86-027-87173753
Single or multiple dose of HW243040 will be administered orally.
Single or multiple dose of placebo will be administered orally.
A Phase Ia Clinical Trial of HW241045
A PhaseⅠ Study of HW252001 in Healthy Subjects
A Phase I Study of HW201877 in Healthy Subjects
A Study to Evaluate HB0034 in Healthy Chinese Adult Participants
A Phase 1 Clinical Study in Healthy Participants
A Study to Evaluate HB0034 in Healthy Adult Participants
A Phase I Study of HW241045 in Healthy Subjects
Phase 1a Study in Healthy Participants